Even prostate tumors resistant to standard treatments responded to an experimental molecule in animal studies, raising the possibility of a different approach to advanced disease.

Most cancer drugs work by blocking proteins or signaling pathways that help tumors grow. Researchers at the University of Michigan Health Rogel Cancer Center are testing a different approach. Instead of blocking two cancer-driving proteins separately, they have developed a molecule that locks them together, disrupting their activity and showing promising results against prostate cancer.

The approach targets the androgen receptor (AR) and a helper protein called p300, which work together to activate genes that fuel prostate cancer growth.

“Our molecule acts like a molecular brace, connecting these two cancer-driving proteins in an abnormal configuration that traps them in an inactive state,” said senior study author Arul M. Chinnaiyan, MD, PhD, director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at Michigan Medicine.

“This shuts down two oncogenic signaling pathways simultaneously, enabling highly effective killing of tumor cells while sparing normal cells. Our preclinical findings suggest that this approach could offer a more effective treatment strategy for prostate cancer,” Chinnaiyan stated.

It has been revealed that the researchers call the approach DALTAC, short for domain-alteration chimeras. It builds on a growing field known as chemically induced proximity, which uses small molecules to bring proteins together and change how they function. Related approaches include PROTACs, which trigger the breakdown of specific proteins, and transcriptional/epigenetic chemically induced proximity (TCIP), which alters gene regulation.

“Our molecules consist of two inhibitors joined by a carefully designed short linker. By gluing two cancer-driving proteins together, they alter the proteins’ natural interactions,” noted senior study author Shaomeng Wang, PhD, Warner-Lambert/Parke-Davis Professor in Medicine, professor of internal medicine, pharmacology and medicinal chemistry, and director of the Michigan Center for Therapeutic Innovation.

The team tested DALTAC molecules in prostate cancer cell lines, mouse models, and three-dimensional organoids derived from human cells. The molecules were more effective at killing tumor cells than combining separate AR and p300 inhibitors, with less toxicity to normal cells. In animal studies, they produced lasting responses and worked against tumors resistant to standard treatments.

Industry observers note that “Our optimized molecule is approximately 1,000 times more potent in tumor cells than the combination of inhibitors targeting these proteins separately, while sparing normal cells that lack these interactions. We also optimized the molecules for oral bioavailability, a key step toward developing a pill for patients,” Wang remarked.

The findings, published in Nature, resulted from a collaboration between Chinnaiyan’s laboratory, which specializes in prostate cancer biology, and Wang’s laboratory, which focuses on medicinal chemistry and drug discovery.

“These are remarkable preclinical results,” Chinnaiyan remarked. “The durable responses suggest an opportunity to develop a more effective treatment for advanced prostate cancer, including castration-resistant prostate cancer, if these findings translate to patients.”.

The research remains at the preclinical stage, and the approach has not yet been tested in humans.

“Our teams are working closely to identify a drug candidate suitable for testing in human clinical trials,” Wang said.

The researchers also believe that changing how proteins interact could offer a broader strategy for developing treatments against other cancers and protein targets beyond AR and p300.

Reference: “Domain-alteration chimeras rewire oncogenic complexes in prostate cancer” by Jie Luo, Jianzhang Yang, Jean Ching-Yi Tien, Mi Wang, Sumit Das, Xiaoju Wang, Eleanor Young, Jelena Tošović, Rahul Mannan, Weiguo Xiang, Xia Jiang, Jocelyn Cai, Yihan Liu, Kenneth Gu, Somnath Mahapatra, Shiting Li, Yitong Yin, Sanjana Eyunni, Abigail J. Todd, Shicheng Jin, Xuhong Cao, Fengyun Su, Stephanie J. Miner, Ranga Sudharshan, Arvind Rao, Abhijit Parolia, Yuanyuan Qiao, Shaomeng Wang and Arul M. Chinnaiyan, 11 November 2026, Nature. DOI: 10.1038/s41586-026-11262-4.

This work was supported by the Rogel Cancer Center Proteomics Resource Facility Shared Resource.

Sources indicate that disclosure: Wang and Chinnaiyan are cofounders of and hold equity in Medsyn Biopharma. The University of Michigan has filed patents related to the AR-p300 DALTACs, which have been licensed to Medsyn. U-M has received a research contract from Medsyn, for which Wang serves as the principal investigator.

Never miss a breakthrough: Join the SciTechDaily newsletter.Follow us on Google and Google News.

→ Read original article